Stock Events

Mannkind 

$6.13
67
+$0.11+1.83% Wednesday 20:00

Statistics

Day High
6.24
Day Low
5.9
52W High
6.44
52W Low
3.17
Volume
2,361,364
Avg. Volume
2,754,064
Mkt Cap
1.72B
P/E Ratio
125.2
Dividend Yield
-
Dividend
-

Upcoming

5
NOV
Earnings
 

Earnings

5NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.05
-0.02
0.01
0.04
Expected EPS
0.025
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MNKD. It's not an investment recommendation.
Alphabet
73232
GOOGL
Apple
63973
AAPL
Microsoft
59623
MSFT
Amazon
55040
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap141.43B
Sanofi, with its diabetes and insulin products, competes directly with MannKind's inhaled insulin, Afrezza.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk is a leading company in diabetes care with a wide range of insulin products, competing in the same market as MannKind.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly is a major player in the diabetes care market, offering insulin and other diabetes treatments that compete with MannKind's offerings.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca operates in the diabetes care sector, offering products that compete with MannKind's diabetes treatments.
Merck
MRK
Mkt Cap300.25B
Merck produces diabetes medications, including oral treatments that serve as alternatives to MannKind's inhaled insulin.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol-Myers Squibb offers a range of diabetes treatments, competing in the broader diabetes care market against MannKind.
Tandem Diabetes Care
TNDM
Mkt Cap2.85B
Tandem Diabetes Care specializes in insulin delivery systems, offering products that can be seen as alternatives to MannKind's Afrezza.
Insulet
PODD
Mkt Cap14.22B
Insulet Corporation provides innovative insulin management systems, competing in the insulin delivery market alongside MannKind.
Dexcom
DXCM
Mkt Cap27.79B
DexCom, Inc. specializes in glucose monitoring systems, which are essential for diabetes management, indirectly competing with MannKind by offering complementary diabetes care solutions.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories offers glucose monitoring systems and other diabetes care products, competing in the broader market for diabetes management solutions.

Analyst Ratings

8.63$Average Price Target
The highest estimate is $12.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Show more...
CEO
Michael Castagna
Employees
411
Country
US
ISIN
US56400P7069

Listings

F
DE
NNFN.F
XNAS
US
MNKD